• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经化学性痴呆诊断的分析前样本处理和样本稳定性测试。

Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics.

机构信息

Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

出版信息

J Alzheimers Dis. 2011;25(4):739-45. doi: 10.3233/JAD-2011-110212.

DOI:10.3233/JAD-2011-110212
PMID:21593568
Abstract

Preanalytical sample handling and storage procedures play an extremely important role in reliably measuring neurochemical dementia diagnostics (NDD) biomarkers: Aβ(1-40), Aβ(1-42), Tau, and pTau181. To test different handling and storage conditions, the following protocols were applied: (a) storage at room temperature for one week, (b) deep-freezing and thawing up to three cycles, (c) deep-freezing, thawing and keeping under +4°C for two days before the analysis, and (d) long-term stability of a deeply frozen sample. Between the first and the seventh day of the storage at room temperature, the percentage of the concentrations (compared to the starting concentrations) fluctuated: 104.3-105.3, 97.6-93.2, 100.6-96.8, and 97.9-90.2 for Aβ(1-40), Aβ(1-42), Tau, and pTau181, respectively. Re-freezing cycles resulted in the percentage fluctuations of the concentrations: 101.1-105.5, 95.4-99.7, 98.3-100.0, and 100.5-101.4 for Aβ(1-40), Aβ(1-42), Tau, and pTau181, respectively. Keeping previously frozen/thawed samples under +4°C for two days resulted in the percentage differences of the concentrations: +15.9, +2.2, -1.1, and -0.1 for Aβ(1-40), Aβ(1-42), Tau, and pTau181, respectively. During long-term stability, the coefficients of linear correlation (R(2)) were: Aβ(1-40), 0.007; Aβ(1-42), 0.02; Tau, 0.011; and pTau181, 0.02, and the corresponding inter-assay coefficients of variation: 13.9%, 13.9%, 11.0%, and 10.7% for Aβ(1-40), Aβ(1-42), Tau, and pTau181, respectively. We conclude that the NDD biomarkers are relatively stable when the cerebrospinal fluid sample is kept at room temperature for about four days; one or two thawing/refreezing cycles do not profoundly affect the biomarkers concentrations, however three cycles result in increased unsystematic variation. The four biomarkers seem to be stable in a sample stored deeply frozen for more than two years.

摘要

在可靠地测量神经化学痴呆诊断(NDD)生物标志物:Aβ(1-40)、Aβ(1-42)、Tau 和 pTau181 方面,预分析样本处理和储存程序起着极其重要的作用。为了测试不同的处理和储存条件,采用了以下方案:(a)在室温下储存一周,(b)深冻和解冻多达三个循环,(c)深冻、解冻并在分析前保持在+4°C 下两天,以及(d)深冻样本的长期稳定性。在室温下储存的第一天到第七天之间,浓度的百分比波动如下:Aβ(1-40)为 104.3-105.3%、Aβ(1-42)为 97.6-93.2%、Tau 为 100.6-96.8% 和 pTau181 为 97.9-90.2%。再冷冻循环导致浓度百分比波动:Aβ(1-40)为 101.1-105.5%、Aβ(1-42)为 95.4-99.7%、Tau 为 98.3-100.0% 和 pTau181 为 100.5-101.4%。将先前冷冻/解冻的样品保持在+4°C 下两天会导致浓度的百分比差异:Aβ(1-40)为+15.9%、Aβ(1-42)为+2.2%、Tau 为-1.1% 和 pTau181 为-0.1%。在长期稳定性期间,线性相关系数(R(2))为:Aβ(1-40)为 0.007;Aβ(1-42)为 0.02;Tau 为 0.011;pTau181 为 0.02,相应的批内变异系数为:Aβ(1-40)为 13.9%、Aβ(1-42)为 13.9%、Tau 为 11.0% 和 pTau181 为 10.7%。我们得出结论,当脑脊液样本在室温下保存约四天时,NDD 生物标志物相对稳定;一个或两个解冻/再冷冻循环不会深刻影响生物标志物浓度,但三个循环会导致非系统性变化增加。这四种生物标志物在深冻储存超过两年的样本中似乎稳定。

相似文献

1
Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics.神经化学性痴呆诊断的分析前样本处理和样本稳定性测试。
J Alzheimers Dis. 2011;25(4):739-45. doi: 10.3233/JAD-2011-110212.
2
Assessment of Preanalytical Cerebrospinal Fluid Handling and Storage Factors on Measurement of Aβ1-42, Aβ1-40, and pTau181 Using an Automated Chemiluminescent Platform.使用自动化化学发光平台评估分析前脑脊液处理和储存因素对 Aβ1-42、Aβ1-40 和 pTau181 测量的影响。
J Appl Lab Med. 2024 Jul 1;9(4):789-802. doi: 10.1093/jalm/jfae033.
3
Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42).脑脊液延迟储存对磷酸化tau蛋白(181)、总tau蛋白和β-淀粉样蛋白(1-42)浓度的影响。
Neurosci Lett. 2007 May 1;417(2):193-5. doi: 10.1016/j.neulet.2007.02.045. Epub 2007 Feb 22.
4
Bacterial contamination and the transport vial material affect cerebrospinal fluid concentrations of β-Amyloid and Tau protein as determined by enzyme immunoassay.细菌污染和运输小瓶材料会影响酶联免疫吸附法测定的β-淀粉样蛋白和 Tau 蛋白的脑脊液浓度。
Dement Geriatr Cogn Disord. 2011;32(2):126-34. doi: 10.1159/000330912. Epub 2011 Sep 23.
5
Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.不同基质作为神经化学性痴呆诊断潜在质量控制样本的比较
J Alzheimers Dis. 2016 Mar 1;52(1):51-64. doi: 10.3233/JAD-150883.
6
Intrathecal IgG synthesis in patients with alterations in the neurochemical dementia diagnostics.鞘内 IgG 合成在神经化学性痴呆诊断改变的患者中。
J Alzheimers Dis. 2010;19(4):1199-203. doi: 10.3233/JAD-2010-1313.
7
Pre-analytical factors influencing the stability of cerebrospinal fluid proteins.影响脑脊液蛋白质稳定性的分析前因素。
J Neurosci Methods. 2013 May 15;215(2):234-40. doi: 10.1016/j.jneumeth.2013.03.011. Epub 2013 Mar 26.
8
Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.阿尔茨海默病的脑脊液生物标志物:在同质单中心人群中的诊断性能。
J Alzheimers Dis. 2011;24(3):537-46. doi: 10.3233/JAD-2011-101878.
9
The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF).前分析因素对脑脊液中蛋白质组和选定代谢物稳定性的影响。
J Proteome Res. 2009 Dec;8(12):5511-22. doi: 10.1021/pr9005876.
10
Added diagnostic value of CSF biomarkers in differential dementia diagnosis.脑脊液生物标志物对鉴别痴呆诊断的附加诊断价值。
Neurobiol Aging. 2010 Nov;31(11):1867-76. doi: 10.1016/j.neurobiolaging.2008.10.017. Epub 2009 Jan 15.

引用本文的文献

1
Standardized Procedures for Blood and Cerebrospinal Fluid Collection and Storage in Neurodegenerative Biomarker Research: A Comprehensive Review.神经退行性生物标志物研究中血液和脑脊液采集与储存的标准化程序:综述
Dement Neurocogn Disord. 2025 Jul;24(3):162-173. doi: 10.12779/dnd.2025.24.3.162. Epub 2025 Jul 17.
2
Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer's Disease Patient Cohorts.蛋白质组学发现和验证新型液体生物标志物以改善阿尔茨海默病患者队列中的患者选择和临床结局预测
Proteomes. 2022 Aug 1;10(3):26. doi: 10.3390/proteomes10030026.
3
Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort.
建立阿尔茨海默病中心巴塞罗那队列 AT(N)分层的脑脊液阿尔茨海默病生物标志物内部截断值。
Int J Mol Sci. 2022 Jun 21;23(13):6891. doi: 10.3390/ijms23136891.
4
Associations of sleep characteristics with alpha-synuclein in cerebrospinal fluid in older adults.老年人脑脊液中α-突触核蛋白与睡眠特征的关联。
Ann Clin Transl Neurol. 2020 Oct;7(10):2026-2034. doi: 10.1002/acn3.51204. Epub 2020 Sep 19.
5
First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays.首个用于校准商业免疫分析的经过认证的β淀粉样蛋白 1-42 参考物质。
Alzheimers Dement. 2020 Nov;16(11):1493-1503. doi: 10.1002/alz.12145. Epub 2020 Aug 4.
6
Towards a unified protocol for handling of CSF before β-amyloid measurements.建立用于β-淀粉样蛋白检测前脑脊液处理的统一方案。
Alzheimers Res Ther. 2019 Jul 19;11(1):63. doi: 10.1186/s13195-019-0517-9.
7
Derivation of cutoffs for the Elecsys amyloid β (1-42) assay in Alzheimer's disease.阿尔茨海默病中Elecsysβ淀粉样蛋白(1-42)检测临界值的推导
Alzheimers Dement (Amst). 2018 Aug 11;10:698-705. doi: 10.1016/j.dadm.2018.07.002. eCollection 2018.
8
Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease.脑脊液分装的实验室间能力验证方案:基于阿尔茨海默病生物标志物的实施和评估。
Alzheimers Res Ther. 2018 Aug 28;10(1):87. doi: 10.1186/s13195-018-0418-3.
9
Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.血浆神经丝轻链作为阿尔茨海默病神经退行性变的潜在生物标志物。
Alzheimers Res Ther. 2018 Jul 28;10(1):71. doi: 10.1186/s13195-018-0404-9.
10
Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.在脑脊液生物标志物谱中加入 Aβ42/40 比值可提高轻度认知障碍患者潜在阿尔茨海默病性痴呆的预测价值。
Alzheimers Res Ther. 2018 Mar 20;10(1):33. doi: 10.1186/s13195-018-0362-2.